Study highlights the need for PrEP and other HIV prevention strategies for pregnant women and new mothers in high-prevalence settings.
The Fair Pricing Coalition is working with pharmaceutical companies to ensure fair prices for new HIV drugs on par with those of older medications.
Presentations on women in research at this year's Conference on Retroviruses and Opportunistic Infections highlighted the lack of inclusion, offered ideas on how to remedy the situation, and showed how one woman moved from advocate to researcher.
Two video interviews with federal HIV leaders who share their perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
The CDC has released new data at the Conference on Retroviruses and Opportunistic Infections (CROI) estimating that only a small percentage of people most at risk for HIV infection have actually been prescribed pre-exposure prophylaxis (PrEP).
The lack of Medicaid expansion in the South is creating worse racial disparities in the U.S., according to researchers and medical providers discussing the HIV care cascade at CROI 2018.
Results from a proof-of-principle study in macaques showing that treatment with broadly neutralising antibodies might play a role in key stages for an HIV cure.
Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.
Dual Therapy Can Reduce TB Prophylaxis From Nine Months to One: Fewer Side Effects and More People Complete Treatment
New results presented at CROI 2018 from a large international study using a simplified approach to prevent TB have the potential to dramatically improve outcomes for HIV positive people.
24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.